NYSE:CC - Chemours Stock Price, Forecast & News

Chemours trades on the New York Stock Exchange (NYSE) under the ticker symbol "CC."

Chemours announced a quarterly dividend on Wednesday, October 30th. Stockholders of record on Friday, November 15th will be paid a dividend of $0.25 per share on Monday, December 16th. This represents a $1.00 dividend on an annualized basis and a dividend yield of 6.91%. The ex-dividend date is Thursday, November 14th. View Chemours' Dividend History.

Chemours Co (NYSE:CC) announced its quarterly earnings data on Monday, November, 4th. The specialty chemicals company reported $0.59 earnings per share for the quarter, beating analysts' consensus estimates of $0.56 by $0.03. The specialty chemicals company earned $1.39 billion during the quarter, compared to analyst estimates of $1.40 billion. Chemours had a return on equity of 58.38% and a net margin of 7.24%. The business's revenue for the quarter was down 14.6% on a year-over-year basis. During the same period last year, the company posted $1.49 EPS. View Chemours' Earnings History.

Chemours is scheduled to release their next quarterly earnings announcement on Thursday, February 13th 2020. View Earnings Estimates for Chemours.

Chemours will be holding an earnings conference call on Thursday, February 13th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Chemours issued an update on its FY19 earnings guidance on Monday, November, 4th. The company provided earnings per share (EPS) guidance of $2.37-3.08 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.47.

12 equities research analysts have issued twelve-month price targets for Chemours' shares. Their forecasts range from $14.50 to $42.00. On average, they expect Chemours' stock price to reach $23.15 in the next year. This suggests a possible upside of 60.0% from the stock's current price. View Analyst Price Targets for Chemours.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chemours in the last year. There are currently 7 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Chemours.

Media stories about CC stock have trended somewhat negative this week, InfoTrie reports. The research group scores the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Chemours earned a news sentiment score of -1.4 on InfoTrie's scale. They also gave news stories about the specialty chemicals company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Chemours.

Chemours saw a drop in short interest in December. As of December 31st, there was short interest totalling 16,370,000 shares, a drop of 5.9% from the December 15th total of 17,390,000 shares. Based on an average daily volume of 2,490,000 shares, the days-to-cover ratio is presently 6.6 days. Currently, 10.1% of the shares of the company are short sold. View Chemours' Current Options Chain.

Some companies that are related to Chemours include Johnson Matthey (JMPLY), Huntsman (HUN), W. R. Grace & Co (GRA), Ashland Global (ASH), KURARAY CO LTD/ADR (KURRY), Univar (UNVR), Balchem (BCPC), Ingevity (NGVT), Innospec (IOSP), Olin (OLN), PQ Group (PQG), GCP Applied Technologies (GCP), Livent (LTHM), Innophos (IPHS) and Hawkins (HWKN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Chemours investors own include E I Du Pont De Nemours And Co (DD), Micron Technology (MU), NVIDIA (NVDA), AT&T (T), Alibaba Group (BABA), Cisco Systems (CSCO), Johnson & Johnson (JNJ), Energy Transfer LP Unit (ET), DowDuPont (DWDP) and Pfizer (PFE).

Chemours' stock is owned by a number of of retail and institutional investors. Top institutional investors include DNB Asset Management AS (0.40%), New York State Teachers Retirement System (0.17%), Traynor Capital Management Inc. (0.13%), Heritage Investors Management Corp (0.08%), Arizona State Retirement System (0.06%) and Nisa Investment Advisors LLC (0.05%). Company insiders that own Chemours stock include Amy Trojanowski, Bradley J Bell, David C Shelton, E Bryan Snell, Erich Parker, Mark Newman, Mark P Vergnano, Mary B Cranston, Paul Kirsch, Richard H Brown and Susan M Kelliher. View Institutional Ownership Trends for Chemours.

CC stock was sold by a variety of institutional investors in the last quarter, including NEXT Financial Group Inc, Janney Montgomery Scott LLC, Boenning & Scattergood Inc., Arizona State Retirement System, Rothschild Investment Corp IL, State of Alaska Department of Revenue, Heritage Investors Management Corp and New York State Teachers Retirement System. Company insiders that have sold Chemours company stock in the last year include Amy Trojanowski, Mark Newman and Paul Kirsch. View Insider Buying and Selling for Chemours.

CC stock was purchased by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC, Traynor Capital Management Inc., DNB Asset Management AS, Patriot Financial Group Insurance Agency LLC, FNY Investment Advisers LLC and State of Michigan Retirement System. Company insiders that have bought Chemours stock in the last two years include Bradley J Bell, David C Shelton, E Bryan Snell, Mark Newman, Mark P Vergnano, Mary B Cranston, Richard H Brown and Susan M Kelliher. View Insider Buying and Selling for Chemours.

Shares of CC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CC stock can currently be purchased for approximately $14.47.

Chemours has a market capitalization of $2.37 billion and generates $6.64 billion in revenue each year. The specialty chemicals company earns $995 million in net income (profit) each year or $5.67 on an earnings per share basis. Chemours employs 7,000 workers across the globe.View Additional Information About Chemours.

The official website for Chemours is http://www.chemours.com/.

Chemours' mailing address is 1007 MARKET STREET, WILMINGTON DE, 19801. The specialty chemicals company can be reached via phone at 302-773-1000 or via email at [email protected]